- Lobbying
- Lobbying by GENZYME CORPORATION
Lobbying Relationship
Bills mentioned
H.R.3590: Patient Protection and Affordable Care Act
Sponsor: Charles B. Rangel (D-N.Y.)
H.R.3962: Preservation of Access to Care for Medicare Beneficiaries and Pension...
Sponsor: John D. Dingell (D-Mich.)
H.R.3200: America's Affordable Health Choices Act of 2009
Sponsor: John D. Dingell (D-Mich.)
S.1679: Affordable Health Choices Act
Sponsor: Tom Harkin (D-Iowa)
H.R.1548: Pathway for Biosimilars Act
Sponsor: Anna G. Eshoo (D-Calif.)
H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act
Sponsor: Henry A. Waxman (D-Calif.)
H.R.5629: Pathway for Biosimilars Act
Sponsor: Anna G. Eshoo (D-Calif.)
H.R.1956: Patient Protection and Innovative Biologic Medicines Act of 2007
Sponsor: Jay Inslee (D-Wash.)
H.R.1038: Access to Life-Saving Medicine Act
Sponsor: Henry A. Waxman (D-Calif.)
H.R.6331: Medicare Improvements for Patients and Providers Act of 2008
Sponsor: Charles B. Rangel (D-N.Y.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Howard Cohen Mr. | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate
U.S. Senate,
U.S. Senate
U.S. Senate
U.S. Senate
Centers For Medicare and Medicaid Services (CMS)
U.S. Senate
U.S. Senate
Centers For Medicare and Medicaid Services (CMS)
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate